Enfuvirtide: The Peptide That Blocks HIV Entry

Peptide-Based HIV Vaccines

36 amino acids

Enfuvirtide (T-20) is a 36-amino-acid synthetic peptide that mimics part of HIV's own gp41 protein to block the virus from fusing with human cells.

Cooper and Lange, Lancet Infect Dis, 2004

Cooper and Lange, Lancet Infect Dis, 2004

View as image

Every antiretroviral drug approved before 2003 targeted HIV after it had already entered the cell. Enfuvirtide, sold as Fuzeon, changed that. It was the first drug to stop HIV at the front door, preventing the virus from fusing with the host cell membrane in the first place.^[1] It was also a landmark in peptide therapeutics: a 36-amino-acid synthetic peptide, designed by studying the virus's own fusion machinery, that proved peptides could be viable drugs for infectious disease. The story of enfuvirtide's development, from a peptide fragment called DP-178 to a globally approved medicine, is one of the clearest examples of how understanding viral biology at the molecular level can produce an entirely new class of therapy. For broader context on how peptides are being used against HIV, enfuvirtide remains the founding case study.

How HIV fuses with cells and why it matters

HIV enters cells through a multi-step process involving two envelope glycoproteins: gp120 and gp41. First, gp120 binds to the CD4 receptor on the target cell. This triggers a conformational change that exposes gp120's binding site for a co-receptor (CCR5 or CXCR4). Co-receptor binding then triggers gp41 to undergo its own conformational rearrangement.^[1]

The gp41 rearrangement is the critical step enfuvirtide targets. When gp41 is activated, it inserts a fusion peptide into the target cell membrane. Two regions of gp41, called heptad repeats 1 and 2 (HR1 and HR2), then fold back on each other to form a six-helix bundle. This bundle pulls the viral and cell membranes together, forcing them to fuse. The virus's genetic material then enters the cell.^[3]

This fusion mechanism presented a clear therapeutic target. If a molecule could bind HR1 before HR2 folds onto it, the six-helix bundle would never form, and fusion would be physically blocked.

Discovery: mapping gp41 with overlapping peptides

In 1993, researchers at Duke University took a systematic approach to finding fusion-blocking peptides. They synthesized a series of overlapping peptides corresponding to different regions of the gp41 ectodomain and tested each one for its ability to inhibit HIV-mediated cell-to-cell fusion in vitro.^[2]

One peptide stood out. DP-178, a 36-amino-acid sequence corresponding to the HR2 region of gp41, inhibited HIV fusion at nanomolar concentrations. The mechanism was biomimetic: DP-178 essentially impersonated the HR2 region of gp41, binding to HR1 and occupying the site that native HR2 would normally engage. With HR1 already occupied by the synthetic peptide, the viral gp41 could not fold into the six-helix bundle, and fusion was blocked.^[2]

This was an elegant design principle: use the virus's own structural blueprint against it. DP-178 did not need to enter the cell or target an intracellular enzyme. It worked outside the cell, at the point of contact between virus and host.

First human trial: proof that a peptide could suppress HIV

DP-178, now designated T-20, entered clinical testing in 1996 under development by Trimeris, a biotech company founded specifically to develop fusion inhibitors. The first human trial, published by Kilby and colleagues in Nature Medicine in 1998, was a landmark in both HIV and peptide therapeutics.^[3]

Sixteen HIV-positive patients received T-20 as monotherapy (without other antiretrovirals) via continuous intravenous infusion for 14 days. At the highest dose (100 mg twice daily), viral load dropped by up to 1.5 log10 copies/mL. This was a substantial reduction for a single agent, particularly one with a completely novel mechanism of action.^[3]

The trial proved several things at once. A synthetic peptide could achieve clinically meaningful antiviral activity in humans. The extracellular fusion-blocking mechanism worked in vivo, not just in cell culture. And the drug was tolerated, though injection site reactions were common.

Phase III trials and FDA approval

In 1999, Trimeris partnered with Hoffmann-La Roche to complete development. The Phase III program consisted of two parallel trials: TORO-1 (T-20 vs. Optimized Regimen Only, conducted in North and South America) and TORO-2 (conducted in Europe and Australia).^[1]

Both trials enrolled heavily treatment-experienced patients who had failed multiple antiretroviral regimens. The median patient had been treated with 12 prior antiretrovirals over 7 years. Median baseline viral load was approximately 5.2 log10 copies/mL, and median CD4 count was 88 cells/mm3. These were patients running out of options.^[1]

In both trials, enfuvirtide plus an individually optimized background regimen demonstrated superior virological and immunological outcomes compared to optimized background therapy alone. At 24 weeks in TORO-1, 37% of patients receiving enfuvirtide achieved viral loads below 400 copies/mL, compared to 16% in the control group. TORO-2 showed similar results: 34% versus 12%. CD4 counts increased more in the enfuvirtide groups, with mean increases approximately 45-65 cells/mm3 greater than controls. The differences were statistically significant and clinically meaningful in a population where any additional viral suppression represented a real therapeutic gain.^[1]

These were patients for whom conventional antiretroviral therapy was failing. Many had viruses resistant to drugs from three or more classes. In this context, adding enfuvirtide, a drug with a mechanism of action completely independent from all existing antiretrovirals, provided an orthogonal therapeutic attack. Resistance to protease inhibitors, reverse transcriptase inhibitors, or integrase inhibitors did not confer cross-resistance to enfuvirtide, because the drug's target (extracellular gp41) was entirely distinct.

The FDA approved enfuvirtide on March 13, 2003, making it the first antiretroviral to target viral entry and the first injectable peptide approved for HIV treatment. The European Medicines Agency granted approval shortly after. It was indicated for treatment-experienced patients, in combination with other antiretrovirals, where existing regimens had failed.

Manufacturing: the hardest peptide to mass-produce

Enfuvirtide's 36-amino-acid sequence made it one of the longest and most complex synthetic peptides in pharmaceutical manufacturing. Producing it required 106 chemical reactions, with each amino acid coupling step needing to proceed at very high efficiency to avoid accumulation of impurities.^[1]

The synthesis used a convergent strategy: the peptide was assembled in fragments (typically three pieces of 10-13 amino acids each), which were then purified individually and linked together through native chemical ligation or fragment condensation. Each coupling step needed to exceed 99% efficiency; even a fraction of a percent loss at each step compounded across 35 amide bonds, degrading overall yield. Even with this approach, manufacturing costs were extraordinary. At launch, the annual cost per patient was approximately $25,000, making enfuvirtide one of the most expensive antiretrovirals available. Roche built a dedicated production facility in Boulder, Colorado, to manufacture the drug at sufficient scale.

The manufacturing challenge had scientific implications beyond cost. It demonstrated that large synthetic peptides could be produced at commercial scale, a technical achievement that influenced subsequent peptide drug development. But it also made the case for investing in longer-acting formulations, oral delivery strategies, and smaller peptide derivatives that might be simpler to manufacture.

Resistance and clinical limitations

Like all antiretrovirals, enfuvirtide faces resistance. Mutations develop in the HR1 domain of gp41, specifically in the region spanning amino acid positions 36 to 45, which is the binding site for the drug. Mutations at position 38 are particularly common and can confer moderate to high-level resistance. Combinations of mutations within this region can produce over 100-fold reductions in drug susceptibility.^[1]

This resistance pattern has a notable feature: the mutations that reduce enfuvirtide binding also tend to reduce viral fitness, meaning the resistant virus replicates less efficiently. This creates a partial virological benefit even when resistance emerges, as the virus pays a replication cost for escaping the drug.

Injection site reactions were the most common adverse effect. Nearly all patients experienced some degree of pain, erythema, or nodule formation at injection sites. The requirement for twice-daily subcutaneous injections, combined with injection site reactions, created significant adherence challenges. Many patients found the regimen burdensome compared to oral antiretroviral pills.

These limitations, cost, injection burden, and the arrival of new oral drug classes (integrase inhibitors, CCR5 antagonists), progressively narrowed enfuvirtide's clinical use. By the late 2000s, the approval of raltegravir (2007), maraviroc (2007), and later dolutegravir (2013) and bictegravir (2018) gave treatment-experienced patients oral alternatives with simpler dosing and fewer side effects. Enfuvirtide remains available and is still used in patients with multi-drug-resistant HIV who have exhausted other options, but it is no longer a first-line or common choice. Global prescriptions have declined substantially since peak use in the mid-2000s.

Enfuvirtide's legacy in peptide drug development

Enfuvirtide's significance extends well beyond its clinical niche. It established several principles that continue to influence peptide therapeutics.

First, it proved that biomimetic peptides, molecules designed to impersonate part of a pathogen's own machinery, could work as drugs. This principle has since been applied to peptide fusion inhibitors targeting other viruses, including coronaviruses. Researchers have developed pan-coronavirus fusion inhibitors based on similar HR2-mimetic designs.^[5]

Second, it demonstrated that extracellular targets, specifically protein-protein interactions on the cell surface, are druggable by peptides. Most small molecule drugs target intracellular enzymes. Enfuvirtide showed that a peptide could intervene in a dynamic conformational process happening outside the cell, a concept now central to many peptide drug design programs.

Third, it exposed the limitations that subsequent peptide drugs have worked to overcome: short half-life, injection requirement, manufacturing complexity, and cost. Next-generation fusion inhibitor peptides have incorporated lipidation, PEGylation, and structural modifications to extend half-life and reduce dosing frequency.^[4] Peptide-liposome conjugates of enfuvirtide-derived sequences have shown enhanced potency in preclinical models.^[6]

The development of enfuvirtide also influenced the broader field of antiviral peptide drug discovery, where AI-driven approaches are now being used to design next-generation antiviral peptides with improved stability and potency.^[5]

The Bottom Line

Enfuvirtide (T-20/Fuzeon) was the first drug to block HIV at the point of cell entry, using a 36-amino-acid synthetic peptide that mimics part of the virus's own gp41 fusion machinery. Discovered in 1993, first tested in humans in 1998, and approved by the FDA in 2003, it proved that biomimetic peptides targeting extracellular protein-protein interactions could achieve clinically meaningful antiviral activity. Manufacturing complexity, twice-daily injections, and the arrival of simpler oral drugs limited its widespread use, but enfuvirtide remains a critical option for multi-drug-resistant HIV and a foundational case study in peptide drug development.

Frequently Asked Questions

What is enfuvirtide and how does it work?

Enfuvirtide (brand name Fuzeon, also called T-20) is a 36-amino-acid synthetic peptide that blocks HIV from entering human cells. It works by binding to the HR1 region of the viral protein gp41, preventing the six-helix bundle formation that is required for viral and cell membrane fusion.^[1] Without this fusion step, HIV cannot deliver its genetic material into the target cell.

Why was enfuvirtide a breakthrough in HIV treatment?

Enfuvirtide was the first antiretroviral to block HIV entry, rather than targeting viral enzymes after the virus is already inside the cell. It was also the first injectable peptide approved for HIV and demonstrated that biomimetic peptides could achieve clinically meaningful antiviral activity in humans. In Phase III trials, it produced superior viral suppression in patients who had failed multiple prior regimens.^[3]

Why is enfuvirtide not commonly used today?

Enfuvirtide requires twice-daily subcutaneous injections, causes injection site reactions in most patients, and costs approximately $25,000 per year. The arrival of potent oral drugs, particularly integrase inhibitors like dolutegravir and bictegravir, provided simpler, more tolerable alternatives. Enfuvirtide is now reserved for patients with multi-drug-resistant HIV who have exhausted other options.

How was the enfuvirtide peptide discovered?

Researchers at Duke University synthesized overlapping peptides corresponding to different regions of HIV's gp41 protein and tested each for fusion-blocking activity. One peptide, DP-178 (later renamed T-20), corresponding to the HR2 region of gp41, inhibited HIV fusion at nanomolar concentrations by mimicking the virus's own structural element and competitively blocking it.^[2]

Does HIV develop resistance to enfuvirtide?

Yes. Resistance mutations arise in the HR1 domain of gp41, particularly at positions 36-45. Single mutations at position 38 can confer moderate to high resistance, and combinations of mutations can reduce drug effectiveness by over 100-fold. However, resistance mutations also reduce viral fitness, meaning the resistant virus replicates less efficiently.^[1]

What did enfuvirtide teach us about peptide drugs?

Enfuvirtide proved three key principles: biomimetic peptides (designed to copy part of a pathogen) can be effective drugs; extracellular protein-protein interactions are druggable by peptides; and large synthetic peptides can be manufactured at commercial scale, though at high cost. These lessons shaped the development of peptide drugs for other viruses, cancers, and metabolic diseases.^[1]